Table 4 Univariate and multivariate analyses of factors for OS.

From: Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma

Variable

Univariate analysis

Multivariate analysis

p-value

Odds ratio

95% CI

p-value

Age, < 75 versus ≥ 75

 < 0.001

0.583

0.428–0.795

0.001

Sex, male versus female

0.212

   

PS, < 1 versus ≥ 1

0.005

0.867

0.554–1.357

0.528

Etiology HBV versus HCV vs others

0.908

   

m-ALBI grade, 1/2a versus 2b

 < 0.001

0.468

0.336–0.650

 < 0.001

Maximum nodule diameter (< 30 versus ≥ 30)

0.002

0.756

0.552–1.032

0.081

Macrovascular invasion (no/yes)

0.001

0.559

0.375–0.833

0.001

Extrahepatic spread (No/Yes)

0.001

0.638

0.399–0.889

0.002

AFP, < 400 versus  ≥ 400 ng/mL

0.002

0.702

0.542–1.028

0.064

DCP, < 400 versus ≥ 400 mAU/mL

0.008

0.888

0.657–1.199

0.438

Discontinuation due to AE (+/−)

 < 0.001

1.931

1.438–2.593

 < 0.001

Sequential therapy (+/−)

 < 0.001

0.494

0.366–0.667

 < 0.001

  1. PS performance status, HBV hepatitis B virus, HCV hepatitis C virus, ALBI score Albumin-bilirubin score, BCLC Barcelona Clinic Liver Cancer, l AFP α-fetoprotein, DCP des-γ-carboxy prothrombin, AE adverse event.
Back to article page